Macroplastique implantation system for female stress urinary incontinence: long-term follow-up.
2/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
15 patients were reassessed by means of objective and subjective parameters at 6, 12, 24, and 60 months after last treatment.
I · Intervention 중재 / 시술
periurethral injection of MIS under local anesthesia
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] The MIS produced promising long-term subjective and objective outcomes, as well as long-lasting improvements in QoL. It should be considered a good option for certain cases of female SUI.
【연구 목적】 본 연구는 고유 괄약근 기능 부전(intrinsic sphincter deficiency)으로 인한 여성 스트레스 요실금(stress urinary incontinence) 환자에게 Macroplastique 이식 시스템(Macroplastique implantation system)을 적용한 후 60개월간의 장기적인 치료 효과와 삶의 질(q
APA
Tamanini JT, D'Ancona CA, Netto NR (2006). Macroplastique implantation system for female stress urinary incontinence: long-term follow-up.. Journal of endourology, 20(12), 1082-6. https://doi.org/10.1089/end.2006.20.1082
MLA
Tamanini JT, et al.. "Macroplastique implantation system for female stress urinary incontinence: long-term follow-up.." Journal of endourology, vol. 20, no. 12, 2006, pp. 1082-6.
PMID
17206907
Abstract
[PURPOSE] To evaluate the 60-month outcome of the Macroplastique Implantation System (MIS) for the treatment of female stress urinary incontinence (SUI) caused by intrinsic sphincter deficiency evaluated by objective and subjective measures, including Quality of Life (QoL) impact.
[PATIENTS AND METHODS] Twenty-one women, mean age 47.4 years, with urodynamically diagnosed intrinsic sphincter deficiency were enrolled. They were assessed preoperatively by physical examination, QoL (King's Health Questionnaire), Stamey grading of incontinence, pad usage, 1-hour pad-weight test, and urodynamic testing. Patients underwent periurethral injection of MIS under local anesthesia. After 24-month follow-up, six patients were discharged from the group, and the remaining 15 patients were reassessed by means of objective and subjective parameters at 6, 12, 24, and 60 months after last treatment.
[RESULTS] Patients' QoL improved in all domains throughout the study. The overall subjective success rate was 80%. At 60 months, pad usage was reduced from a mean of 3.5/day to 0.9/day, and the 1-hour pad weight decreased from 53.8 to 5.9 g. Valsalva leak-point pressure testing demonstrated a 73.3% rate of cure/improvement. There was no significant statistical difference assessed by Stamey grading and objective cure at 6, 12, 24, and 60 months of follow-up. The data showed a stable overall outcome from 6 to 60 months.
[CONCLUSION] The MIS produced promising long-term subjective and objective outcomes, as well as long-lasting improvements in QoL. It should be considered a good option for certain cases of female SUI.
[PATIENTS AND METHODS] Twenty-one women, mean age 47.4 years, with urodynamically diagnosed intrinsic sphincter deficiency were enrolled. They were assessed preoperatively by physical examination, QoL (King's Health Questionnaire), Stamey grading of incontinence, pad usage, 1-hour pad-weight test, and urodynamic testing. Patients underwent periurethral injection of MIS under local anesthesia. After 24-month follow-up, six patients were discharged from the group, and the remaining 15 patients were reassessed by means of objective and subjective parameters at 6, 12, 24, and 60 months after last treatment.
[RESULTS] Patients' QoL improved in all domains throughout the study. The overall subjective success rate was 80%. At 60 months, pad usage was reduced from a mean of 3.5/day to 0.9/day, and the 1-hour pad weight decreased from 53.8 to 5.9 g. Valsalva leak-point pressure testing demonstrated a 73.3% rate of cure/improvement. There was no significant statistical difference assessed by Stamey grading and objective cure at 6, 12, 24, and 60 months of follow-up. The data showed a stable overall outcome from 6 to 60 months.
[CONCLUSION] The MIS produced promising long-term subjective and objective outcomes, as well as long-lasting improvements in QoL. It should be considered a good option for certain cases of female SUI.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 해부 | periurethral
|
scispacy | 1 | ||
| 질환 | stress urinary incontinence
|
C0042025
Urinary Stress Incontinence
|
scispacy | 1 | |
| 질환 | SUI
→ stress urinary incontinence
|
C0042025
Urinary Stress Incontinence
|
scispacy | 1 | |
| 질환 | sphincter deficiency
|
scispacy | 1 | ||
| 질환 | incontinence
|
C0021167
Incontinence
|
scispacy | 1 | |
| 질환 | MIS
→ Macroplastique Implantation System
|
scispacy | 1 | ||
| 기타 | female
|
scispacy | 1 | ||
| 기타 | women
|
scispacy | 1 | ||
| 기타 | MIS
→ Macroplastique Implantation System
|
scispacy | 1 |
MeSH Terms
Adult; Female; Follow-Up Studies; Humans; Middle Aged; Quality of Life; Surgery, Plastic; Time Factors; Treatment Outcome; Urinary Incontinence, Stress